Lifeline Scientific, Inc.

Life Science Holdings, Inc.

Other

Organ Recovery Systems, Inc.

Therapeutic Peptides, Inc.

Donald R Owen

David C Kravitz

Dickon Isaacs

John Brassil

Andrew Burroughs

Kelvin G M Brockbank

Douglas A Schein

Richard T Fraser

Stanley Harris

Dennis J Steibel

Dennis Steibel, Jr

Lili Fan

Christopher G Curtis

Kelvin Gm Brockbank

Otha J Jacobus

Andrews Burroughs

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. In perfusion, organ perfusion pressure is preferably controlled in response to a sensor disposed in an end of tubing placed in the organ, by a pneumatically pressurized medical fluid reservoir, providing perfusion pressure fine tuning, overpressurization prevention and emergency flow cut-off. In the hypothermic mode, the organ is perfused with a medical fluid, preferably a simple crystalloid solution containing antioxidants, intermittently or in slow continuous flow. The medical fluid may be fed into the organ from an intermediary tank having a low pressure head to avoid organ overpressurization. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.

Apparatus and method for maintaining and/or restoring viability of organs

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.

The present invention is directed to biosurfactants that can self-assemble or auto-aggregate into polymeric micellar structures and their use in topically-applied dermatologic products. The invention relates in particular to polymeric acylated biosurfactants (PABs) conforming to the formula Acyl-AA-Term where Acyl is an 8- to 22-membered carbon chain, branched or unbranched, saturated or unsaturated, AA is a consecutive sequence of four to nine amino acid residues, where at least one, preferably at least two of the amino acid residues is charged, and Term is an acid C-terminus or an amide C-terminus. PABs of the present invention have low critical micelle concentrations (predominantly less than about 100 ppm) in an aqueous environment of Minimal Essential Media (MEM) and can lower the surface tension in the aqueous MEM environment to less about 50 dynes/cm2. They also have the ability to increase metabolic soluble proteins.

Polymeric biosurfactants

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. In perfusion, organ perfusion pressure is preferably controlled in response to a sensor disposed in an end of tubing placed in the organ, by a pneumatically pressurized medical fluid reservoir, providing perfusion pressure fine tuning, overpressurization prevention and emergency flow cut-off. In the hypothermic mode, the organ is perfused with a medical fluid, preferably a simple crystalloid solution containing antioxidants, intermittently or in slow continuous flow. The medical fluid may be fed into the organ from an intermediary tank having a low pressure head to avoid organ overpressurization. Preventing overpressurization prevents or reduces damage to vascular endothelial lining and to organ tissue in general. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.

Oligomeric acylated biosurfactants ('OABs') having low critical micelle concentrations of from about 1.0 ppm to about 200 ppm, preferably less than about 50 ppm, in an aqueous solution of Minimal Essential Media that can lower the surface tension in the aqueous MEM environment to less than about 50 dynes/cmand have the ability to increase metabolic soluble proteins and/or increase synthesis of extracellular skin matrix proteins and/or increase rates of cell turnover while at the same time exhibiting comparatively low toxicity&#x2014;preferably, an LDof greater 200 ppm in 37 year-old female fibroblast cells. Another aspect of the present invention is directed to the use of OABs in formulations that are topically-applied, by which is meant the formulation is placed in direct contact with the skin, hair and nails as well as mucosa of the eyes, ears, nose, mouth, anus and vagina.

Oligomeric biosurfactants in dermatocosmetic compositions

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. In the hypothermic mode, the organ is perfused with a medical fluid, preferably a simple crystalloid solution containing antioxidants, intermittently or in slow continuous flow. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.

Method for controlling perfusion of an organ

Method of determining transport and/or storage parameters for maintaining viability of an organ

An organ perfusion apparatus and method monitor, sustain and/or restore viability of organs and preserve organs for storage and/or transport. The method includes perfusing the organ at hypothermic and/or normothermic temperatures, preferably after hypothermic organ flushing for organ transport and/or storage. The method can be practiced with prior or subsequent static or perfusion hypothermic exposure of the organ. Organ viability is restored by restoring high energy nucleotide (e.g., ATP) levels by perfusing the organ with a medical fluid, such as an oxygenated cross-linked hemoglobin-based bicarbonate medical fluid, at normothermic temperatures. In perfusion, organ perfusion pressure is preferably controlled in response to a sensor disposed in an end of tubing placed in the organ, by a pneumatically pressurized medical fluid reservoir, providing perfusion pressure fine tuning, overpressurization prevention and emergency flow cut-off. In the hypothermic mode, the organ is perfused with a medical fluid, preferably a simple crystalloid solution containing antioxidants, intermittently or in slow continuous flow. The medical fluid may be fed into the organ from an intermediary tank having a low pressure head to avoid organ overpressurization. Preventing overpressurization prevents or reduces damage to vascular endothelial lining and to organ tissue in general. Viability of the organ may be automatically monitored, preferably by monitoring characteristics of the medical fluid perfusate. The perfusion process can be automatically controlled using a control program.

Method of transporting and storing a kidney

Method for maintaining and/or restoring viability of organs

An organ perfusion apparatus and method monitor, sustain and/or restore viability of the organs and preserve organs for storage and/or transport. Other apparatus include an organ transporter, an organ cassette and an organ diagnostic device.

A resuscitation apparatus includes a fluid pathway in fluid communication with a source of medical fluid, an interface unit for attaching the fluid pathway to the cardiovascular system of a mammal suffering from impaired blood flow in order to establish an artificial circulation in the mammal utilizing the medical fluid, and heat exchange apparatus that provides intense cooling to quickly chill the medical fluid a sufficient amount to slow a metabolic rate of an organ of a mammal into which the medical fluid is introduced. A method of treating anoxic and/or ischemic brain injury in a mammal suffering from impaired blood flow includes utilizing heat exchange apparatus that provides intense cooling to quickly chill a medical fluid a sufficient amount to slow a metabolic rate of a brain of a mammal into which the medical fluid is introduced, and introducing the chilled medical fluid into the cardiovascular system of a mammal suffering from impaired blood flow in order to establish an artificial circulation in the mammal, whereby the mammal remains substantially neurologically intact.

Growing community of inventors

New Orleans, LA, United States of America

Donald R Owen